{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '6.5.', 'Blinding', 'This will be a double-blind double dummy study and the following will apply.', \"The investigator or treating physician may unblind a subject's treatment\", 'assignment only in the case of an emergency OR in the event of a serious', 'medical condition when knowledge of the study treatment is essential for the', 'appropriate clinical management or welfare of the subject as judged by the', 'investigator.', \"Investigators have direct access to the subject's individual study treatment.\", 'It is preferred (but not required) that the investigator first contacts the Medical', 'Monitor or appropriate GSK study personnel to discuss options before unblinding', \"the subject's treatment assignment.\", 'If GSK personnel are not contacted before the unblinding, the investigator must', 'notify GSK as soon as possible after unblinding, but without revealing the', 'treatment assignment of the unblinded subject, unless that information is', 'important for the safety of subjects currently in the study.', 'The date and reason for the unblinding must be fully documented in the eCRF', \"A subject will be withdrawn if the subject's treatment code is unblinded by the\", \"investigator or treating physician. GSK's Global Clinical Safety and Pharmacovigilance\", '(GCSP) staff may unblind the treatment assignment for any subject with an SAE. If the', 'SAE requires that an expedited regulatory report be sent to one or more regulatory', \"agencies, a copy of the report, identifying the subject's treatment assignment, may be sent\", 'to investigators in accordance with local regulations and/or GSK policy.', '6.6.', 'Packaging and Labeling', 'The contents of the label will be in accordance with all applicable regulatory', 'requirements.', '6.7.', 'Preparation/Handling/StoragelAccountability', 'No special preparation of the study treatment is required.', 'The investigator or designee must confirm appropriate temperature conditions', 'have been maintained during transit for all study treatment received and any', 'discrepancies are reported and resolved before use of the study treatment.', 'Only subjects enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure environmentally controlled and monitored', '(manual or automated) area in accordance with the labelled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (i.e. receipt, reconciliation and final disposition records).', '39']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Further guidance and information for final disposition of unused study treatment', 'are provided in the SRM.', 'All ELLIPTA DPI study treatment should be stored up to 25\u00b0C (77\u00b0F). Each', 'ELLIPTA DPI contains 30 doses and is packaged in a foil pouch with a desiccant', 'sachet and stored in a carton. The inhaler should not be used for more than 30 days', 'after opening the foil. The sites must maintain a daily temperature log for the', 'investigational product.', 'Salmeterol DISKUS should be stored up to 25 \u00b0C.', 'Under normal conditions of handling and administration, study treatment is not', 'expected to pose significant safety risks to site staff. Take adequate precautions to', 'avoid direct eye or skin contact and the generation of aerosols or mists. In the case of', 'unintentional occupational exposure notify the monitor, Medical Monitor and/or GSK', 'study contact.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '6.7.1.', 'Study Treatment Return', 'All used and unused ELLIPTA and DISKUS inhalers and albuterol/salbutamol will be', 'returned to GSK at the end of the study to be available for disposal. In some instances', 'for sites outside the US, study supplies will be disposed of locally either by the site, the', 'country medical department or third-party vendor. Detailed instructions for the return of', 'the study drug can be found in the SRM.', 'Study treatment will be collected at Visit 3, 4 and 5 or at the Early Withdrawal Visit, if', 'applicable.', 'For any ELLIPTA or DISKUS inhaler that fails to function properly, the subject should', 'return to the clinic as soon as possible to obtain a new inhaler. The site will contact the', 'RAMOS NG to obtain a new treatment pack number for the subject and dispense a new', \"study treatment kit from the site's investigational product supply as instructed by the\", 'RAMOS NG', 'In addition, any ELLIPTA that fails to function properly must be identified and returned', 'to GSK for testing.', '6.8.', 'Compliance with Study Treatment Administration', 'When subjects self-administer study treatment(s) at home, compliance with study', 'treatment(s) will be assessed through querying the subject during the site visits and', 'through study drug compliance assessed at Visits 2, 3, 4 and 5 documented in the source', 'documents and eCRF. A record of the number of ELLIPTA and DISKUS dispensed and', 'the number of doses inhaled by each subject must be maintained and reconciled with', 'study treatment and compliance records. Treatment start and stop dates, including dates', 'for treatment delays if any will also be recorded in the eCRF.', '40']\n\n###\n\n", "completion": "END"}